Vestal Point Capital LP purchased a new stake in Perrigo Company plc (NYSE:PRGO – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 375,000 shares of the company’s stock, valued at approximately $9,641,000. Vestal Point Capital LP owned about 0.27% of Perrigo at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of PRGO. Barclays PLC raised its holdings in shares of Perrigo by 44.8% in the third quarter. Barclays PLC now owns 120,502 shares of the company’s stock valued at $3,160,000 after buying an additional 37,268 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Perrigo by 10.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 304,948 shares of the company’s stock valued at $7,840,000 after buying an additional 28,843 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Perrigo during the fourth quarter worth about $691,000. Janney Montgomery Scott LLC increased its stake in shares of Perrigo by 39.1% during the fourth quarter. Janney Montgomery Scott LLC now owns 90,624 shares of the company’s stock worth $2,330,000 after acquiring an additional 25,472 shares during the period. Finally, Sound Income Strategies LLC increased its stake in shares of Perrigo by 28.6% during the fourth quarter. Sound Income Strategies LLC now owns 482,811 shares of the company’s stock worth $12,413,000 after acquiring an additional 107,427 shares during the period. 95.91% of the stock is owned by hedge funds and other institutional investors.
Perrigo Trading Up 2.8%
Shares of PRGO opened at $27.03 on Monday. The company has a current ratio of 2.56, a quick ratio of 1.77 and a debt-to-equity ratio of 0.94. The firm’s 50-day moving average is $26.25 and its two-hundred day moving average is $26.15. Perrigo Company plc has a twelve month low of $23.14 and a twelve month high of $30.93. The firm has a market capitalization of $3.72 billion, a P/E ratio of -23.10 and a beta of 0.45.
Perrigo Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 17th. Shareholders of record on Friday, May 30th will be issued a $0.29 dividend. This represents a $1.16 annualized dividend and a dividend yield of 4.29%. The ex-dividend date is Friday, May 30th. Perrigo’s dividend payout ratio (DPR) is presently -88.55%.
Analyst Upgrades and Downgrades
Separately, StockNews.com lowered shares of Perrigo from a “buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $33.00.
Get Our Latest Report on Perrigo
Insider Buying and Selling at Perrigo
In related news, EVP Ronald Craig Janish sold 7,800 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $27.44, for a total transaction of $214,032.00. Following the transaction, the executive vice president now owns 33,666 shares of the company’s stock, valued at approximately $923,795.04. This represents a 18.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.70% of the company’s stock.
Perrigo Company Profile
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Further Reading
- Five stocks we like better than Perrigo
- How to Capture the Benefits of Dividend Increases
- Is NIO Stock Set for a Comeback? Fundamentals Say Yes
- What is MarketRank� How to Use it
- Best Value Stocks According to Morningstar in 2025
- How to Invest in Biotech Stocks
- Deere Powers Ahead: Q2 Beat, Analyst Boosts, More Upside
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.